ledipasvir/sofosbuvir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 54 Diseases   8 Trials   8 Trials   2662 News 


«12345678910111213...2324»
  • ||||||||||  Mycobutin (rifabutin) / Pfizer, Lupin
    Successful, Concurrent Treatment of a Patient with Pulmonary Tuberculosis and Hepatitis C Infection Using Therapeutic Drug Monitoring (Room 207-208 (South Building, Level 2), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_5360;    
    have developed a method to measure the DAA levels of ledipasvir and sofosbuvir (LDV/SOF) in blood...Sputum samples were smear positive for acid fast bacilli (AFB) and culture positive for Mycobacterium Tuberculosis (MTB) with a positive MTB polymerase chain reaction and no mutations for isoniazid or rifampin resistance on molecular analysis...This case illustrates the successful, simultaneous use of LDV/SOF and rifabutin in HCV/TB coinfection with significant public health implications. More robust research will determine if this treatment method is generalizable.
  • ||||||||||  Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie
    TREATMENT WITH SOF/VEL/VOX IN HIV/HCV-COINFECTED PATIENTS PREVIOUSLY EXPOSED TO DAAs ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_1126;    
    Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) is a pan-genotypic direct active antiviral (DAA) regimen approved for patients who have previously failed anti-HCV treatment with other DAAs...The type of previous regimens included sofosbuvir/ledipasvir in 50% patients, ombitasvir/paritaprevir/ritonavir plus dasabuvir in 9.4%, sofosbuvir plus daclatasvir in 9.4%, elbasvir/grazoprevir in 9.4%, glecaprevir/pibrentasvir in 9.4% and 13.4% other regimens...Liver cirrhosis and genotype did not influence treatment response (SVR by ITT 90% for cirrhosis and 85.8% for G3). Our findings suggest that SOF/VEL/VOX is a highly effective regimen for treatment of coinfected patients previously failing to DAA regimens, across all genotypes and in the presence of cirrhosis.
  • ||||||||||  Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
    Clinical, Reimbursement, Journal, Medicare:  Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D. (Pubmed Central) -  Jan 20, 2022   
    The results of this cross-sectional study suggest that authorized generic drugs for insulin and direct-acting antiviral agents may lower out-of-pocket spending for patients but are unlikely to provide savings for Part D plans or Medicare. Instead, these drugs allow manufacturers to offer products at a lower list price without materially lowering net prices or profits.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Clinical, Journal:  Responsible Inclusion of Pregnant Individuals in Eradicating Hepatitis C Virus. (Pubmed Central) -  Jan 13, 2022   
    Our systematic review of publications on HCV treatment with DAAs in pregnancy revealed only one interventional study, which evaluated sofosbuvir/ledipasvir in 8 pregnant individuals...The exclusion of pregnant individuals without justification denies them and their offspring access to potential health benefits, raising justice concerns considering growing data on DAA safety and global efforts to promote equitable and comprehensive HCV eradication. Finally, we propose a path forward for research and treatment programs during pregnancy to help advance the goal of HCV elimination.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea (clinicaltrials.gov) -  Nov 29, 2021   
    P=N/A,  N=1081, Completed, 
    It could be an excellent strategy to eliminate HCV infection in HIV-coinfected MSM. Recruiting --> Completed | N=3000 --> 1081 | Trial completion date: Jan 2022 --> Jun 2021 | Trial primary completion date: Jan 2022 --> Jun 2021
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Clinical, Journal, HEOR:  Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C. (Pubmed Central) -  Nov 24, 2021   
    Recruiting --> Completed | N=3000 --> 1081 | Trial completion date: Jan 2022 --> Jun 2021 | Trial primary completion date: Jan 2022 --> Jun 2021 Overall, SOF/VEL and LDV/SOF regimens are more likely to be cost-effective among various subgroups of Chinese patients with CHC.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Clinical, Journal:  Ledipasvir/sofosbuvir-associated photosensitivity in a case with chronic hepatitis C. (Pubmed Central) -  Nov 6, 2021   
    The most common adverse events associated with DAAs are fatigue and headache, but various abnormal cutaneous effects including photosensitivity have been reported, especially with the use of simeprevir/sofosbuvir. Here we present a case developing photosensitivity due to ledipasvir/sofosbuvir during the treatment of chronic hepatitis C.
  • ||||||||||  Arbidol (umifenovir) / Pharmstandard, Prezcobix (darunavir/cobicistat) / Gilead, J&J, Xofluza (baloxavir marboxil) / Roche, Shionogi
    Clinical, Review, Journal:  Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials. (Pubmed Central) -  Nov 4, 2021   
    Further larger RCTs in other countries are warranted to support these findings. In contrast, the present findings of limited RCTs did not indicate the use of lopinavir/ritonavir, sofosbuvir/ledipasvir, baloxavir, umifenovir, and darunavir/cobicistat in the treatment of patients hospitalized for COVID-19.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    [VIRTUAL] PARTNERSHIPS FOR ELIMINATION: AMBULATORY CARE CLINICAL PHARMACISTS DISMANTLING BARRIERS TO HEPATITIS C CURE () -  Oct 21, 2021 - Abstract #AASLD2021AASLD_1165;    
    Treatment breakdown was: 29 (76.3%) glecaprevir/ pibrentasvir, 6 (15.8%) sofosbuvir/velpatasvir & 3 (7.9%) ledipasvir/sofosbuvir. Integration of clinical pharmacist services within the VH program has contributed to the team based approach in dismantling barriers of HCV cure, including cost and access, drug interactions, adverse reactions, specialist requirements and nonadherence .
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    [VIRTUAL] HEPATITIS C TREATMENT IN THE UNITED STATES, 2014–2020 () -  Oct 21, 2021 - Abstract #AASLD2021AASLD_1158;    
    This average number of persons living with hepatitis C treated is below the number needed to ensure elimination of hepatitis C as a public health threat in the United States by 2030. Public health interventions such as increased testing and improved linkage to care for groups experiencing disproportionate impact, and removal of restrictions to treatment are critical to improve access to treatment and eliminate hepatitis C as a public health threat in the United States .
  • ||||||||||  [VIRTUAL] TRENDS IN HEPATOCELLULAR CARCINOMA AND ANTIVIRAL HEPATITIS TREATMENT IN OLDER AMERICANS () -  Oct 21, 2021 - Abstract #AASLD2021AASLD_913;    
    Despite a marked increase in the effectiveness and frequency of HCV treatment in 2014 and 2015, HCV-attributable HCC continued to rise through 2015. Future studies should examine the incidence of HCV-attributable HCC among older Americans in subsequent years to assess the effect of the introduction of DAA therapies for HCV in this population .